Spots Global Cancer Trial Database for allogeneic transplantation
Every month we try and update this database with for allogeneic transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies | NCT01385072 | Relapsed and Re... | Double matched ... | 18 Years - | Rabin Medical Center | |
| Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | NCT00460447 | Acute Myeloid L... Allogeneic Tran... | Gemtuzumab Ozog... | 18 Years - 70 Years | University Hospital Carl Gustav Carus | |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | NCT02145403 | Hematologic Mal... Relapse Graft-Versus-Ho... | Carfilzomib Tacrolimus | 18 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | NCT00129155 | Hematological M... Allogeneic Tran... | treosulfan | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma | NCT01440556 | Multiple Myelom... Allogeneic Tran... | 18 Years - 80 Years | Azienda Ospedaliera San Giovanni Battista | ||
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | NCT02627573 | Leukemia, Chron... Myelodysplastic... Leukemia, Myelo... | Unrelated allog... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Cyclophosphamid... Thymoglobulin | 18 Years - 75 Years | St. Petersburg State Pavlov Medical University | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation | NCT01460420 | Hematologic Mal... Multiple Myelom... | Bz (Bortezomib) Len (lenalidomi... | 18 Years - 70 Years | Stichting European Myeloma Network | |
| Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | NCT04334993 | Philadelphia-Ne... High-Risk Cance... | Blinatumomab | 18 Years - 30 Years | Israeli Medical Association | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) | NCT00350818 | Myelodysplastic... Leukemia | Azacitidine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis | NCT05158608 | Graft Versus Ho... Hematologic Mal... Cyclophosphamid... | Post-transplant... Post-transplant... | 18 Years - | National Research Center for Hematology, Russia | |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | NCT01572662 | Leukemia Acute Myeloid L... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Non-Hodgkins Ly... Hodgkins Lympho... Multiple Myelom... Myelodysplastic... | Fludarabine mon... Busulfan Stem Cell Infus... Tacrolimus Methotrexate G-CSF | 5 Years - 75 Years | M.D. Anderson Cancer Center | |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | NCT02799147 | Leukemia, Acute... Acute Myeloid L... Mixed-Lineage A... | Allogeneic stem... Fludarabine mon... Busulfan Bendamustine | 18 Years - 60 Years | St. Petersburg State Pavlov Medical University | |
| MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | NCT00129155 | Hematological M... Allogeneic Tran... | treosulfan | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas | NCT01786018 | B-cell Lymphoma... | Thiotepa Busulfan Fludarabin transplant (HCT... Cytoreduction Immunosuppressi... Cyclosporine Methotrexate ATG Collection and ... | 18 Years - 65 Years | Azienda Ospedaliera San Giovanni Battista | |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | NCT00038831 | Acute Myelogeno... Myelodysplastic... Chronic Lymphoc... | Mylotarg Fludarabine Melphalan Anti-thymocyte ... Stem cell trans... | 12 Years - 75 Years | M.D. Anderson Cancer Center | |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | NCT01020175 | Acute Leukemia Chronic Myeloge... Myelodysplastic... | Bone marrow tra... Peripheral bloo... | 18 Years - 55 Years | European Society for Blood and Marrow Transplantation | |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) | NCT01468467 | Leukemia, Myelo... | AC220 | 18 Years - | Daiichi Sankyo | |
| Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant | NCT05849207 | Hematologic Mal... | Cyclophosphamid... | 70 Years - | Cedars-Sinai Medical Center | |
| Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies | NCT00619879 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Lymphoma, Malig... | Myeloablative C... Myeloablative C... Hematopoietic P... CNS radiation t... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | NCT01020175 | Acute Leukemia Chronic Myeloge... Myelodysplastic... | Bone marrow tra... Peripheral bloo... | 18 Years - 55 Years | European Society for Blood and Marrow Transplantation | |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | NCT02145403 | Hematologic Mal... Relapse Graft-Versus-Ho... | Carfilzomib Tacrolimus | 18 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | NCT00460629 | Chronic Myeloid... | Application of ... | 18 Years - 60 Years | University Hospital Carl Gustav Carus | |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines | NCT02580539 | Epstein-Barr Vi... Post-Transplant... Lymphoma | Group A Group B | 18 Years - | Maisonneuve-Rosemont Hospital | |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | NCT00672152 | Acute Myelogeno... Chronic Myeloge... Acute Lymphobla... Myelodysplastic... B Cell Malignan... | WT1 derived pep... | 18 Years - | Duke University | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | NCT04334993 | Philadelphia-Ne... High-Risk Cance... | Blinatumomab | 18 Years - 30 Years | Israeli Medical Association | |
| A Study of the Safety and Efficacy of EBV Specific T-cell Lines | NCT02580539 | Epstein-Barr Vi... Post-Transplant... Lymphoma | Group A Group B | 18 Years - | Maisonneuve-Rosemont Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
